Pharmacokinetic and Pharmacodynamic Considerations of Echinocandin Therapy for Invasive Fungal Infections

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
This CME-certified monograph is intended for Infectious Disease specialists and bone marrow transplant surgeons.

Upon completing this activity, you should be able to:

• Discuss the pharmacokinetic and pharmacodynamic data of echinocandin antifungal therapies.
• Identify and contrast pharmacologic treatment options for the treatment of invasive fungal infections.
• Describe safety and efficacy profiles of echinocandin antifungal therapy when treating invasive fungal infections.

Accreditation:
Millennium CME Institute, Inc., has assumed the responsibility for long-term retention of individual credit records.

Millennium CME Institute, Inc., is accredited by the ACCME to provide continuing medical education for physicians.

Millennium CME Institute, Inc., designates this educational activity for a maximum of .5 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity was prepared in accordance with the ACCME Essentials.

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by James S. Lewis, PharmD; Alexandra Mangili, MD, MPH; Roger P. Clark, DO; and Lisa Davidson, MD.

Release Date: November 2006

Expiration Date: November 30, 2007

© 2006 Millennium CME Institute, Inc.

Faculty Disclosure:
Millennium CME Institute, Inc., endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. All faculty are required to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations and with companies who have provided the commercial support for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no relationships to disclose:

• Roger P. Clark, DO
• Lisa Davidson, MD
• Mark A. Gendreau, MD
• David C. Howard
• Alexandra Mangili, MD, MPH
• Tim I. Robinson

The faculty listed below have declared the following arrangements and/or affiliations:

James S. Lewis, PharmD: Speakers Bureau-Astellas Pharma US, Inc., and Pfizer

Signed Disclosure forms are on file at Millennium CME Institute, Inc.

The opinions expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Astellas Pharma US, Inc., any other manufacturer of pharmaceuticals, or Millennium CME Institute, Inc. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

This Infectious Disease Forum Report^TM was made possible through an educational grant from Astellas Pharma US, Inc.

This CME-certified monograph contains information on commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Directions:
The learner should read the learning objectives and review the activity in its entirety. After reviewing the material, the learner should complete the Activity Self-assessment Test consisting of a series of multiple-choice questions.

Upon successfully completing this activity as designed and achieving a passing score of 70% or higher on the Activity Self-assessment Test, participants will receive a continuing education credit letter awarding the appropriate credit and the Activity Self-assessment Test answers four to six weeks after the receipt of the registration and evaluation materials.

Estimated time to complete this activity as designed is .5 hour.

CME Testing Options